Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin H Eng

Showing results (31-40 of 78) with videos related to

Pageof 8
Sort By:
Scientific Reports|February 18, 2016
Discovery of candidate tumor biomarkers for treatment with intraperitoneal chemotherapy for ovarian cancerBrandon-Luke L Seagle, Kevin H Eng, Judy Y Yeh, et al.
Oncotarget|June 21, 2016
PRAME expression and promoter hypomethylation in epithelial ovarian cancerWa Zhang, Carter J Barger, Kevin H Eng, et al.
Gynecologic Oncology|May 13, 2017
Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancerKevin H Eng, Kayla Morrell, Kristen Starbuck, et al.
Genome Research|February 8, 2020
Alternative polyadenylation drives oncogenic gene expression in pancreatic ductal adenocarcinomaSwati Venkat, Arwen A Tisdale, Johann R Schwarz, et al.
Cancer Treatment and Research Communications|April 11, 2018
LIFETIME PHYSICAL INACTIVITY IS ASSOCIATED WITH LUNG CANCER RISK AND MORTALITYRikki Cannioto, John Lewis Etter, Michael J LaMonte, et al.
Cancers|March 10, 2022
Estrogen Receptor-Beta2 (ERβ2)-Mutant p53-FOXM1 Axis: A Novel Driver of Proliferation, Chemoresistance, and Disease Progression in High Grade Serous Ovarian Cancer (HGSOC)Chetan C Oturkar, Nishant Gandhi, Pramod Rao, et al.
Plos One|November 13, 2018
Prognostic impact of adjuvant chemotherapy treatment intensity for ovarian cancerKristen D Starbuck, J Brian Szender, William D Duncan, et al.
Gynecologic Oncology|April 11, 2017
NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancerJ Brian Szender, Antonios Papanicolau-Sengos, Kevin H Eng, et al.
JCI Insight|February 21, 2020
Prostate tumor-derived GDF11 accelerates androgen deprivation therapy-induced sarcopeniaChunliu Pan, Neha Jaiswal Agrawal, Yanni Zulia, et al.
Gynecologic Oncology|May 11, 2015
TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome AtlasBrandon-Luke L Seagle, Chia-Ping Huang Yang, Kevin H Eng, et al.
Pageof 8

Showing results (31-40 of 78) with videos related to

Sort By:
Pageof 8
Scientific Reports|February 18, 2016
Discovery of candidate tumor biomarkers for treatment with intraperitoneal chemotherapy for ovarian cancerBrandon-Luke L Seagle, Kevin H Eng, Judy Y Yeh, et al.
Oncotarget|June 21, 2016
PRAME expression and promoter hypomethylation in epithelial ovarian cancerWa Zhang, Carter J Barger, Kevin H Eng, et al.
Gynecologic Oncology|May 13, 2017
Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancerKevin H Eng, Kayla Morrell, Kristen Starbuck, et al.
Genome Research|February 8, 2020
Alternative polyadenylation drives oncogenic gene expression in pancreatic ductal adenocarcinomaSwati Venkat, Arwen A Tisdale, Johann R Schwarz, et al.
Cancer Treatment and Research Communications|April 11, 2018
LIFETIME PHYSICAL INACTIVITY IS ASSOCIATED WITH LUNG CANCER RISK AND MORTALITYRikki Cannioto, John Lewis Etter, Michael J LaMonte, et al.
Cancers|March 10, 2022
Estrogen Receptor-Beta2 (ERβ2)-Mutant p53-FOXM1 Axis: A Novel Driver of Proliferation, Chemoresistance, and Disease Progression in High Grade Serous Ovarian Cancer (HGSOC)Chetan C Oturkar, Nishant Gandhi, Pramod Rao, et al.
Plos One|November 13, 2018
Prognostic impact of adjuvant chemotherapy treatment intensity for ovarian cancerKristen D Starbuck, J Brian Szender, William D Duncan, et al.
Gynecologic Oncology|April 11, 2017
NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancerJ Brian Szender, Antonios Papanicolau-Sengos, Kevin H Eng, et al.
JCI Insight|February 21, 2020
Prostate tumor-derived GDF11 accelerates androgen deprivation therapy-induced sarcopeniaChunliu Pan, Neha Jaiswal Agrawal, Yanni Zulia, et al.
Gynecologic Oncology|May 11, 2015
TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome AtlasBrandon-Luke L Seagle, Chia-Ping Huang Yang, Kevin H Eng, et al.
Pageof 8